Avidity Biosciences: Proof-Of-Concept Achieved In DM1 For AOC Platform [Seeking Alpha]
Avidity Biosciences, Inc. (RNA)
Company Research
Source: Seeking Alpha
24K-Production/iStock via Getty ImagesShares of RNA therapeutics pioneer Avidity Biosciences (NASDAQ:neared -60% (since has pared that to-20%).A week ago the companyannounced a positive early readoutOn the other hand, as I understand it, there are still some potential safety issues to better understand here given prior FDA partial clinical hold for unspecified "serious adverse event". So, with a skeptical eye, I look forward to digging deeper to determine if there's enough derisking here to merit consideration in our clinical stage portfolio.ChartFinVizFigure 1:weekly chart (Source: Finviz)When looking at charts, clarity often comes from taking a look at distinct time frames in order to determine important technical levels and get a feel for what's going on. In the weekly chart above, we can see share price gradually decline (albeit in an erratic manner) from above $30 to a low $10 in early December. From there, data readout quickly spiked the share price to the high teens and the sto
Show less
Read more
Impact Snapshot
Event Time:
RNA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RNA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RNA alerts
High impacting Avidity Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
RNA
News
- Avidity Biosciences, Inc. (NASDAQ: RNA) is now covered by analysts at Bank of America Co.. They set a "buy" rating and a $40.00 price target on the stock.MarketBeat
- Artisan International Small-Mid Fund Q1 2024 Earnings Preview [Seeking Alpha]Seeking Alpha
- Strategies for Global Clinical Trials: Clinical Research Without Borders, Upcoming Webinar Hosted by XtalksPR Web
- Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR Newswire
- FYBR, BCRX and SABR are among after hour movers [Seeking Alpha]Seeking Alpha
RNA
Earnings
- 2/28/24 - Miss
RNA
Sec Filings
- 5/6/24 - Form SC
- 4/26/24 - Form ARS
- 4/26/24 - Form DEFA14A
- RNA's page on the SEC website